A Phase Ib/II, Open Label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs BI 836826 (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 06 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2017 Planned End Date changed from 30 Jun 2019 to 11 Nov 2022.
- 03 Oct 2017 Planned primary completion date changed from 30 Jun 2019 to 11 Aug 2020.